The global antibody drug conjugate market size is expected to reach USD 23.9 billion by 2028, according to a new report by Grand View Research Inc. The market is expected to grow at a CAGR of 23.7% from 2021 to 2028. Increasing investment in R&D and advancements in linker technology are expected to boost the growth of the antibody drug conjugates (ADCs) market.Nice to see this growth in the ADC’s market from everything I’m reading the Antibody–drug conjugates (ADCs) are becoming increasingly prominent in the oncology landscape. Exciting prospect for Pab as this is just ONE way our platform can be used.
Ann: PAT-DX3 proof of concept as potential ADC targeting antibody, page-135
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.34M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1283356 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 4958674 | 5 |
View Market Depth
| Last trade - 16.12pm 27/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable